{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T12:15:11Z","timestamp":1698408911571},"reference-count":34,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2023.12229","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T12:44:26Z","timestamp":1695818666000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparison of net adverse clinical events between bivalirudin and heparin as anticoagulants for percutaneous coronary intervention in Chinese patients"],"prefix":"10.3892","volume":"26","author":[{"given":"Lina","family":"Chai","sequence":"first","affiliation":[{"name":"Department of Cardiology, Handan Central Hospital, Handan, Hebei 056002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinjun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Handan Central Hospital, Handan, Hebei 056002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yapei","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Fourth Department of Oncology, Handan Central Hospital, Handan, Hebei 056002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Handan Central Hospital, Handan, Hebei 056002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenzhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Handan Central Hospital, Handan, Hebei 056002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiping","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Handan Central Hospital, Handan, Hebei 056002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhichao","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Handan Central Hospital, Handan, Hebei 056002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenpeng","family":"Qin","sequence":"additional","affiliation":[{"name":"Veteran Cadre Management Section, Handan Central Hospital, Handan, Hebei 056002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"key20231026123232_b1-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/17425247.2022.2044784","article-title":"Drug-eluting stents for the treatment of coronary artery disease: A review of recent advances","volume":"19","author":"Hong","year":"2022","journal-title":"Expert Opin Drug Deliv"},{"key":"key20231026123232_b2-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1136\/heartjnl-2019-315707","article-title":"Recent advances in percutaneous coronary intervention","volume":"106","author":"Hoole","year":"2020","journal-title":"Heart"},{"key":"key20231026123232_b3-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/eurheartj\/ehaa824","article-title":"Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: A 40-year journey","volume":"42","author":"Cao","year":"2021","journal-title":"Eur Heart J"},{"issue":"e23973","key":"key20231026123232_b4-ETM-26-5-12229","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.23973","article-title":"Factors impacting stent thrombosis in patients with percutaneous coronary intervention and coronary stenting: A systematic review and meta-analysis","volume":"14","author":"Nso","year":"2022","journal-title":"Cureus"},{"key":"key20231026123232_b5-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1136\/heartjnl-2014-306685","article-title":"The hypercoagulable profile of patients with stent thrombosis","volume":"101","author":"Loeffen","year":"2015","journal-title":"Heart"},{"key":"key20231026123232_b6-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.2147\/IJGM.S289295","article-title":"Current perspectives on antithrombotic therapy for the treatment of acute coronary syndrome","volume":"15","author":"Towashiraporn","year":"2022","journal-title":"Int J Gen Med"},{"key":"key20231026123232_b7-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"635","DOI":"10.31083\/j.rcm2203074","article-title":"Atrial fibrillation and coronary artery disease: A review on the optimal use of oral anticoagulants","volume":"22","author":"Bocchino","year":"2021","journal-title":"Rev Cardiovasc Med"},{"key":"key20231026123232_b8-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: A North American perspective: 2021 Update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"key":"key20231026123232_b9-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2174\/1871525719666210914110750","article-title":"Direct (new) oral anticoagulants (DOACs): Drawbacks, bleeding and reversal","volume":"20","author":"Karcioglu","year":"2022","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"key20231026123232_b10-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1016\/j.cjca.2022.07.007","article-title":"The evolution of anticoagulation for percutaneous coronary intervention: A 40-year journey","volume":"38 (10 Suppl 1)","author":"Bainey","year":"2022","journal-title":"Can J Cardiol"},{"key":"key20231026123232_b11-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1053\/j.jvca.2019.08.022","article-title":"Role of bivalirudin for anticoagulation in adult perioperative cardiothoracic practice","volume":"34","author":"Erdoes","year":"2020","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"key20231026123232_b12-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.clinthera.2021.03.004","article-title":"Efficacy and safety of bivalirudin during percutaneous coronary intervention in chronic total occlusion: A retrospective study","volume":"43","author":"Zhang","year":"2021","journal-title":"Clin Ther"},{"key":"key20231026123232_b13-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(09)61484-7","article-title":"Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-Year results of a randomised controlled trial","volume":"374","author":"Mehran","year":"2009","journal-title":"Lancet"},{"issue":"5352087","key":"key20231026123232_b14-ETM-26-5-12229","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5352087","article-title":"Safety and efficacy of bivalirudin versus unfractionated heparin monotherapy in patients with CAD and DM undergoing PCI: A retrospective observational study","volume":"2022","author":"Li","year":"2022","journal-title":"Cardiovasc Ther"},{"key":"key20231026123232_b15-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1001\/jama.2015.2323","article-title":"Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: The BRIGHT randomized clinical trial","volume":"313","author":"Han","year":"2015","journal-title":"JAMA"},{"key":"key20231026123232_b16-ETM-26-5-12229","first-page":"246","article-title":"Comparison of the effects of heparin and bivalirudin on percutaneous coronary intervention in female patients with coronary","volume":"49","author":"Chen","year":"2021","journal-title":"Clin J Med Offic"},{"key":"key20231026123232_b17-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","article-title":"Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: The CRUSADE (can rapid risk stratification of unstable angina patients suppress ADverse outcomes with early implementation of the ACC\/AHA guidelines) bleeding score","volume":"119","author":"Subherwal","year":"2009","journal-title":"Circulation"},{"key":"key20231026123232_b18-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"304","DOI":"10.4070\/kcj.2021.0293","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with STEMI","volume":"52","author":"Ki","year":"2022","journal-title":"Korean Circ J"},{"key":"key20231026123232_b19-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the bleeding academic research consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"key20231026123232_b20-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1097\/PCC.0000000000002384","article-title":"Evaluation of bivalirudin as an alternative to heparin for systemic anticoagulation in pediatric extracorporeal membrane oxygenation","volume":"21","author":"Hamzah","year":"2020","journal-title":"Pediatr Crit Care Med"},{"key":"key20231026123232_b21-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1161\/CIRCINTERVENTIONS.110.959098","article-title":"Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention","volume":"4","author":"Kimmelstiel","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"issue":"e25003","key":"key20231026123232_b22-ETM-26-5-12229","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025003","article-title":"Bivalirudin in patients undergoing percutaneous coronary intervention and independent predictors of postoperative adverse events in these patients: A real world retrospective study","volume":"100","author":"Hu","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"932054","key":"key20231026123232_b23-ETM-26-5-12229","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.932054","article-title":"Bivalirudin vs heparin on a background of ticagrelor and aspirin in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A multicenter prospective cohort study","volume":"9","author":"Yu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"key20231026123232_b24-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/S0140-6736(22)01999-7","article-title":"Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomised trial","volume":"400","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"key20231026123232_b25-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/VHRM.S23491","article-title":"Outcome of the HORIZONS-AMI trial: Bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty","volume":"8","author":"Shah","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"key20231026123232_b26-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/00019501-200509000-00010","article-title":"The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention","volume":"16","author":"Keating","year":"2005","journal-title":"Coron Artery Dis"},{"key":"key20231026123232_b27-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.carrev.2017.02.019","article-title":"Bivalirudin versus heparin in women undergoing percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials","volume":"18","author":"Saad","year":"2017","journal-title":"Cardiovasc Revasc Med"},{"key":"key20231026123232_b28-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"S608","DOI":"10.1002\/ccd.26407","article-title":"The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial","volume":"87 (Suppl 1)","author":"Liang","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"issue":"300060520947942","key":"key20231026123232_b29-ETM-26-5-12229","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520947942","article-title":"Efficacy and safety of bivalirudin application during primary percutaneous coronary intervention in older patients with acute ST-segment elevation myocardial infarction","volume":"48","author":"Chen","year":"2020","journal-title":"J Int Med Res"},{"key":"key20231026123232_b30-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/eurheartj\/ehw031","article-title":"Is bivalirudin just an expensive heparin?","volume":"37","author":"Widimsk\u00fd","year":"2016","journal-title":"Eur Heart J"},{"issue":"e00774","key":"key20231026123232_b31-ETM-26-5-12229","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.774","article-title":"A meta-analysis and cost-minimization analysis of bivalirudin versus heparin in high-risk patients for percutaneous coronary intervention","volume":"9","author":"Sun","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"key20231026123232_b32-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1161\/CIRCOUTCOMES.110.957290","article-title":"Cost-effectiveness of targeting patients undergoing percutaneous coronary intervention for therapy with bivalirudin versus heparin monotherapy according to predicted risk of bleeding","volume":"3","author":"Amin","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"key20231026123232_b33-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/heartjnl-2011-301323","article-title":"Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb\/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction","volume":"98","author":"Schwenkglenks","year":"2012","journal-title":"Heart"},{"key":"key20231026123232_b34-ETM-26-5-12229","doi-asserted-by":"publisher","first-page":"761","DOI":"10.4330\/wjc.v9.i9.761","article-title":"Safety, efficiency and cost effectiveness of bivalirudin: A systematic review","volume":"9","author":"Mehrzad","year":"2017","journal-title":"World J Cardiol"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T09:32:40Z","timestamp":1698312760000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2023.12229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,9,27]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2023.12229","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"article-number":"530"}}